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ABSTRACT 
 e design of platinum based drugs is not a new fi eld of 
interest. Platinum complexes are widely used as anticancer 
agents and currently, approximately 30 platinum(II) and 
platinum(IV) entered into some of the phases of clinical trials. A 
special place in today’s research belongs to platinum complexes 
with diammine ligands. A large number of edda (ethylenedi-
amine-N, N’-diacetate)-type ligands and their corresponding 
metal complexes has been successfully synthesized.  is article 
summarizes recent progress in research on edda-type-platinum 
complexes. Some of these agents achieves better eff ect compared 
to the gold standard  (cisplatin). It has been shown that there 
is a possible relationship  between the length of the ligand ester 
group carbon chain  and its  cytotoxic eff ect. In most cases the 
longer the ester chain is the greater is the antitumor activity. Of 
particular interest are the noticeable eff ects of some new plati-
num compound with edda-type ligand on cell lines that  are 
known to have a high level of cisplatin-resistance. Exanimate 
complexes appear to have a diff erent mode of mechanism of 
action compared with cisplatin which includes apoptotic and 
necrotic  cell death.  ere are indications that further investiga-
tions of these compounds may be very useful in overcoming the 
problems associated global cancer statistic.
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SAŽETAK
Kompleski platine koriste se kao osnova za dizajn novih 
lekova. Oni su u širokoj upotrebi kao antitumorski agensi 
i do danas je oko 30 komplesa platine(II) i platine(IV) u 
nekoj od faza kliničkog ispitivanja. Posebno mesto u današ-
njim istaživanjima zauzimaju kompleksi metala sa edda 
ligandima. Uspešno je sintetisan veliki broj novih edda 
liganda i odgovarajućih kompleksa. Neki od ovih agensa 
pokazuju bolju aktivnost od zlatnog standarda, cispla-
tine. Pokazano je da postoji moguća veza između dužine 
ugljovodiničnog lanca estraske grupe liganda i citotoksič-
nog efekta. U većini slučajeva dužina lanca direktno kore-
lira sa antitumorskom aktivnošću. Zabeležena je efi kasni-
ja citotoksična aktivnost određenih kompleska platine sa 
edda ligandima na ćelijskim linijama tumora koji pokazju 
odgovarajući stepen rezistencije na cisplatinu. Ispitivani ko-
mleksi imaju različit mehanizam dejstva od cisplatine, koji 
uključuje elemente nekrotične i programirane ćelijske smrti. 
Postoje nagoveštaji da dalja istraživanja ovih agensa mogu 
biti značajna za prevazilaženje globalnog problema sa ko-
jim se svet danas suočava, a koji se odnosi na stalni porast 
osoba obolelih od karcinoma.
Ključne reči: kompleksi platine, edda ligandi, citotoksičnost
REVIEW PAPER    REVIJALNI RAD    REVIEW PAPER    REVIJALNI RAD    REVIEW PAPER 
286
not show sufficient selectivity towards tumor cells and 
cause nephrotoxicity, ototoxicity, or anemia (23,24). How-
ever, from the chemical standpoint, the platinum(II) com-
plex is highly reactive. It may react with sulphur-contain-
ing amino acids (Cys and Met), such as metallothionein 
and albumin. In the cell, in the [Pt(NH3)2(H2O)2]2+ form, it 
can react with different chemical classes, carbonate ions, 
phosphates, methionine, glutathione or metallothioneins. 
All this greatly reduces efficiency and utilization of this 
drug (3,19,24-27). It has therefore been necessary to syn-
thesize more selective and less reactive molecule. This led 
to platinum complexes of the second and third generation 
(28-30). Complexes of the second generation are structur-
al analogs of cisplatin, designed to overcome the toxicity 
of cisplatin, while the third generation complexes were 
created as even more advanced analogues with the main 
task to act on tumor cells resistant to cisplatin. Since the 
FDA approved cisplatin as drug, seven more platinum(II) 
complexes have been introduced to clinical use: 2 of them 
worldwide (carboplatin and oxaliplatin) and 5 of them 
in certain countries (nedaplatin, loboplatin, heptaplatin, 
miriplatin and cycloplatin) (31-33).
It has been found that each ligand has a role in the 
structure-activity relationship of synthesized complex 
compound. L-ligands, permanent ligands, form the 
strongest bond with platinum and remain intact in the 
final compound of the complex and DNA (34,35). The 
resistance of tumor cells to the drug mainly depends 
on these ligands. Oxaliplatin is an analogue of cisplatin, 
which has a more voluminous and hydrophobic diamino-
cyclohexyl ligand that “fits” in a major DNA groove thus 
preventing access to enzymes which “fix” DNA. The main 
advantage of oxaliplatin compared to cisplatin is that it 
acts on tumor cells resistant to cisplatin. Currently, it 
is the drug of choice for colorectal cancer (21,36). Pt-X 
bond (X is an outgoing ligand) is the weakest, and this is the 
place of possible hydrolysis in the cell. Therefore, this ligand 
directly affects the kinetics of reaction between the drug and 
DNA (34). Modification of these X-ligands can be achieved 
by reducing the number of side reactions in the cell. Both L 
and X ligand groups affect lipophilicity and solubility of 
the complex. Carboplatin (cis-diammine-1,1-cyclobutan-
edicarboxylateplatinum(II)) has in its structure bidentate 
cyclobutane dicarboxylate ligand which has impact on 
reduction of number of side reactions of this drug in the 
cell. These changes eliminated nephrotoxicity of carbo-
platin (23).
Due to the many side reactions of cisplatin and its 
analogues in  cells, QSAR (quantitative structure activi-
ty-relationship) assessments of platinum(IV) complex are 
beginning. These complexes, 5d6 low spin electron con-
figurations of Pt(IV) ion have octahedral geometry, which 
compared to platinum(II) complexes provides two new 
axial ligands, thereby increasing the kinetic stability and 
reducing the reactivity of these complexes compared to 
platinum(II) complexes. These ligands should be lipophilic 
to facilitate easier complex passage through the membrane 
INTRODUCTION
The era of modern medical chemistry, which includes 
drugs based on metals, began with discovery of cispla-
tin (cis-diaminedichloroplatinum(II)) (1). It appears that 
metal complexes are a solid basis for the design of new 
drugs. A vast number of geometric isomers and different 
coordination numbers of metallic ions enable fine-tuning 
of both kinetic (ligands substitution rate) and thermody-
namic (strength of metal-ligand bonds, electrode potential) 
parameters during synthesis of metal complexes – a po-
tential drug (2-5). Ligands play a significant role in design 
and synthesis of novel complexes, both due to their ability 
to recognize sites where a complex should bind in a target 
cell, and the redox processes involved when a  ligand that 
may be released in the cell (6-10). 
Platinum complexes are widely used as anticancer 
agents and currently, approximately 30 platinum(II) and 
platinum(IV) complexes have entered into some phase 
of clinical trial (11). A special place in current research 
belongs to platinum complexes with diamine ligands. 
A large number of edda (ethylenediamine-N, N’-diace-
tate)-type ligands and their corresponding metal complex-
es (platinum, ruthenium, cobalt and palladium) have been 
successfully synthesized (12). Among them, platinum and 
ruthenium complexes stand out due to their anticancer ef-
fects, which have been confirmed on a large panel of differ-
ent tumour cell lines.
DESIGN AND BIOLOGICAL EVOLUTION
OF PLATINUM BASED DRUG
Cisplatin is the first platinum-based drug with anti-
cancer effect approved by the FDA (Food and Drug Ad-
ministration) and it is most efficient in treatment of many 
tumors including testicular, ovarian, kidney and neck can-
cer (2,13). After intravenous administration, cisplatin 
remains structurally unaltereddue to the high concen-
tration of  hloride in blood plasma (100 mM). It reaches 
tumor cells by either simple diffusion through cell mem-
brane or active transport by copper transporter CTR1 (14-
16). Due to much lower concentration of chloride ions in 
cytosol (3-20 mM) compared to extracellular fluid, there 
is rapid hydrolysis and substitution of chloride ligands by 
modified water molecules. After hydrolysis, the platinum 
cationic complex ([Pt(NH3)2(H2O)2]2+) enters nucleus where 
it forms a coordinative bond with nitrogen atoms of nu-
cleic bases of DNA, usually guanine (17,18). A bifunction-
al GG macrochelate is formed through coordination with 
guanine nitrogen atoms from adjacent DNA chains. [Pt(N-
H3)2(H2O)2]2+ represents a chain between DNA strands. The 
modified DNA is permanently damaged and impossible to 
be used for transcription and replication, resulting cell cycle 
arrest and consequently apoptosis (18-21).
Despite extraordinary success of cisplatin, this drug has 
a number of drawbacks (22). For example cisplatin does 
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A series of platinum(IV) complexes similar to JM216 has 
also been synthesized, with aliphatic, aromatic and alicyclic 
amines, with straight and branched chain, which showed 
higher activity compared to cisplatin. Despite major efforts 
and detailed studies and predictions, none of platinum(IV) 
complexes, including JM216, has not been approved for 
clinical use. Very good results of biological tests of oxalip-
latin and satraplatin encouraged the idea of synthesis of 
platinum(II) and platinum(IV) complex with edda type lig-
ands as their analogues, in order to obtain better anti-can-
cer agents (42,43). 
R2EDDATYPE LIGAND 
Since the beginning of platinum derivates explora-
tion, less attention has been given to aminocarboxylate 
ligand complexes. Liu (44) was the first who showed the 
coordination of ethylenediamine-N,N′-diacetate with 
platinum(II). Unfortunately, he obtained [Pt(H2edda)Cl2] 
complex in which both carboxylate groups were protonate, 
mainly due to synthesis conditions, which left platinum(II) 
coordination sphere the same as in [Pt(en)Cl2]. Over the 
coming years, investigations of complexes with edda and 
related ligands have attracted the attention, chiefly because 
the good chelating ability of the ligands which may indicate 
a variety of complexes’ stereochemical and physical prop-
erties. Ethylenediamine-N-N’-diacetic acid (edda) contains 
two nitrogens and also two oxygens as donor atoms. It acts 
as a tetradentate ligand in the case of complete coordina-
tion. R2 edda ligand type belongs to the dialkil esters group of 
ethylenediamine-N-N’-diacetic acid (H2edda), di(izo)propionic 
acid (H2eddp, H2eddip), di-2-(3-cyclohexyl)-propanoic acid 
(H2eddch), di-2-(3methyl)-butanoic adic (H2eddv), di-2-
(4-methyl)-pentanoic acid (H2eddl), as well as propilen-
diamine-N-N’-diacetic acid (H2pdda) (Figure 2). Edda lig-
ands can very easily be esterified, and during the complete 
coordination edda- ligands type esters mainly behave as 
and to make Pt-ligand bond stronger, so there would not 
be any hydrolysis and side reactions. Furthermore, these 
ligands are potential binding sites for so-called carriers in 
cells, nanoparticles that allow smooth passage of the drug 
to target site in a cell. It is assumed that this structure of 
platinum(IV) complex affects stability of the complex, 
which is the basis for their potential oral use (34, 37). 
It was believed  that octahedral platinum(IV) com-
plexes are more inert in blood circulation and that they 
will be activated when they enter the cell. By cell entering 
Pt(IV) complexes will lose Pt(II) species which are re-
sponsible for cytotoxicity (38). It was believed that this 
fact will allow platinum(IV) complexes to be superior over 
the platinum(II) complexes regarding the degree of resist-
ance, side effects and possible oral administration. The 
first attempt to synthesize a whole new drug platinum(IV) 
based line, in context of prodrugs, has been made by 
Rosenberg (6). Platinum(IV) complexes cis-[Pt(NH3)2Cl4], 
trans-[Pt(NH3)2Cl4] and [Pt(en)Cl4] were soon abandoned 
because they showed less anticancer activity then cispla-
tin. By today, two most prosperous agents are satraplatin 
(JM216) and LA-12 (Figure 1) (39, 40). The greatest suc-
cess was with complex of JM216 - satraplatin. Satraplatin 
is a lipophilic molecule, easily enters the cell, it is inert and 
stable, and because of all this has potential for oral admin-
istration. It is reduced within the cell by the cytochrome C, 
and then by hemoglobin as well in the presence of NADH. 
Satraplatin is characterized by a comfort drug use (can be 
used orally) for patient unlike other Pt(II) drugs that can 
only be used intravenously. The presence of intracellular 
agents as glutathione, ascorbic acid and others is required 
for reduction of satraplatin and therefore for its activation 
(41). Also satraplatin can be used for treatment of pros-
tate, lung and ovarian tumors with little signs of nephro-, 
neuro- and ototoxicity. LA12 is a satraplatin analogue and 
future investigation will probably demonstrate that it may 
be used for ovarian carcinoma resistant on cisplatin, or 
even colorectal tumors (42,43).
Figure 1. Structural formulae of platinum drug 
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(NNOH) and ethylenediamine-N,N′-diacetic acid (H2ed-
da) have a different influence on CH1, 41M and Skov-3 
cell line than on cisplatin resistant cell lines (Table 1) (46). 
While platinum(IV) complex with NN’ donor set is 2-5 five 
times more potent against cisplatin sensitive/resistant cell 
lines, in comparison with platinum(II) complex, but with 
complexes with edda ligand situation is entirely different - 
platinum(II) complexes are far more active. Platinum(IV) 
complexes with ligands dialkyl esters of ethylenediamine-N, 
N’-diacetic acid (R2edda) [PtCl4(R2edda)] x H2O (R = Me, 
Et, n-Pr) were also investigated primarily to clarify influ-
ence at length of carbon chain in ester group on antipro-
liferative effect in vitro (Figure 3) (47). Examinations were 
performed on severe human tumor cell lines (Table 1). It 
was shown that by replacing methyl group in ester chain 
by ethyl or propyl group cytotoxic effect will be increased 
- the longer the ester chain is, the greater is the antitumor 
activity. The absence of this trend is observed on DLD-1 
cell line. Complexes [PtCl4(Et2edda)] and [PtCl4(Pr2edda)] 
achieved highest cytotoxic activity on cisplatin-resistant 
bidentate ligands. In some cases, hydrolysis of one or both 
of ester groups occurs, thus the ligands may behave as bi-
dentate or tridentate, respectively (45). 
CYTOTOXICITY OF PLATINUM COMPLEXES
WITH EDDATYPE LIGANDS
Platinum complexes with edda-type ligands
Platinum(II) and platinum(IV) complexes with ehty-
lenediamine ligands, N-(2-hydroxyethyl)ethylenediamine 
(heen), N-N’-bis(2-hydroxyethyl)ehtylenediamine (he2n), 
ehtylenediamine-N, N’-diacetic acid (H2edda) and ehtylen-
ediamine-N-monoacetic acid (hedma) were examined in 
order to reveal their cytotoxicity on different cell lines of 
human ovarian carcinoma (Table 1) (45). These complexes 
have temperate cytotoxic effects, through they were sig-
nificantly lower than those of cisplatin and JM-216. It has 
been proven that platinum(II)/(IV) complexes with multi-
dentate ligands N-(2-hydroxyethyl)ethane-1,2-diamine 
Figure 2. Structural formulae of edda acid types (anionic form)
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Table 1. Cytotoxic eff ect of Platinum complexes with edda ligand type
Ligand type Pt complex
Carbon chain 
in ester group 
(R) Cell line
Cytotoxic eff ect comparing to cisplatin Study
edda
IV Me, Et, n-Pr
testicular germ cell tumors (1411HP, H12.1), 
colon carcinoma (DLD-1), melanoma 
(518A2), liposarcoma
and lung carcinoma (A549)
lower
stronger cytotoxic effi  cacy in cisplatin- 
resistant 1411HP cells (compared to other cell 
lines) [ca. 35–40 μM]
(vs. cisplatin[IC50 2.7 μM])
Kaludjerovic et al 
(2008)  47
II Me, Et, n-Pr
melanoma  (5182A), human thyroid 
carcinoma  (8505C), head and neck tumor 
(A253), cervix (A431), lung (A549), ovarian 
(A2780), breast (MCF-7) and all colon
(HT-29, HCT-8, DLD-1, SW1736)
lower
n-Pr complex showed the highest action 
against ovarian (A2780) cells  [IC50 value of 51 
μM] (vs. cisplatin [IC50 0.55 μM])
Kaludjerovic  et al 
(2014) 48
eddp
IV
Br,J human ovarian cancer (A2780/A2780cisR) lower
A2780 cell line: Pt complexes[IC50 value ca. 
30-90 μM] (vs. cisplatin [IC50 0.2 μM])
A2780cisR cell line: Pt complexes[IC50 value ca. 
90-270 μM] (vs. cisplatin [IC50 3.5 μM])
Sabo et al (2004) 49
Et and n-Pr
ovarian (A2780), cervix (A431), melanoma  
(518A2), lung (A549), head and neck (FaDu), 
colon (HT-29, HCT-8, DLD-1,
8505C, SW480)
lower
PtCl4(n-Pr2eddp)] has highest eff ect on A2780, 
518A2 and A549 cell lines[IC50 value 8.6 μM 
/ 17.99 μM / 20.81 μM] (vs. cisplatin [IC50 0.5 
μM / 1.5 μM / 1.5 μM])
Kaludjerovic et al (2009) 52
n-Bu melanoma (B16) more potently N/A Maksimovic-Ivanic et al (2012) 53
II and IV n-Bu, n-Pe/Br,J
human cervix adenocarcinoma (HeLa), 
human myelogenous leukemia (K562) lower
Pt(dveddp)Cl4 eff ect on K562 cell line is closest 
to cisplatin [IC50 value 5.87 μM]
(vs. cisplatin [IC50 5.0 μM])
Kaludjerovic et al (2005) 50
eddp and
pdda IV
n-Bu, n-Pe/
Br
mouse fi brosarcoma (L929), human 
astrocytoma (U251) comparable
best results were gained with platinum(IV) 
complexes [PtCl4(R2eddp) (K562 cell line [IC50 
value 5.87 μM] vs. cisplatin [IC50 5.0 μM])
Kaludjerovic et al (2005) 51
(S,S) eddp
II and IV i-Pr, i-Bu;
human cervix adenocarcinoma(HeLa), 
human myelogenous leukemia (K562), 
malignant melanoma (Fem-x cell)
lower
Pt(IV) isopropyl (S,S)eddp complex is most 
active [IC50 value 30.48μM / 12.26 μM / 13.68 
μM] (vs. cisplatin [IC50 4.47 μM / 5.77 μM / 
4.7 μM])
Krajcinocic et al (2008) 54
IV
Br,J
rat glioma cell line(C6), human glioma cell 
line(U251), mouse fi brosarcoma
cell line (L929)
lower
IC50 value of cisplatin 9.8 μM / 23.6 μM / 19.3 
μM vs. IC50 values of Pt(IV) complexes  were 
over then 100 μM
Djinovic et al (2010) 55
n-Pr, n-Bu, 
n-Pe
the colon cancer adnocarcinoma cell line 
(HTC-116), breast cancer
cell line (MDA-MB-231)
more potently (n-
Pr and n-Pe)
n-Pr eff ect on HCT-116 cells - [IC50 value of 
77.68 μM] (vs. cisplatin [IC50 263.66 μM])  and 
on MDA-MB-231 cells (72h) [IC50 value of 
64.21 μM] (vs. cisplatin [IC50 114.11 μM])
n-Pe eff ect on HCT-116 cells - [IC50 value of 
96.08 μM] (vs. cisplatin [IC50 263.66 μM])  and 
on MDA-MB-231 cells (24h) [IC50 value of 
238.60 μM] (vs. cisplatin [IC50 425.32 μM])
Stojkovic et al (2014) 56
eddp and (S,S) 
eddp II and IV
i-Pr, i-Bu; 
cyclopentyl
mouse colon cancer (CT26CL25), colon 
cancer (HTC116 and SW620), prostate cancer 
(PC3 and LNCaP), glioblastoma (U251), 
human melanoma (A375), and murine 
melanoma (B16))
more potently 
(Platinum(IV) 
complexes)
IC50 value of platinum(IV) complexes is up to 
3 times lower than that of the corresponding 
platinum(II) complexes
Platinum(IV) complexes on CT26CL25, 
HCT116, SW620, and B16 cell lines) [IC50 ca. 
35–100 μM] (vs. cisplatin[IC50 ca. 45-120 μM])
Kaludjerovic et al (2012) 57
eddip II Et, n-Pr, n-Bu, n-Pe
human colon cancer cell lines (HCT116, 
SW480 and CaCo-2) more potently
n-Bu Pt(II) complex has highest eff ect [IC50 
value 11.23 μM / 5.09 μM / 4.02 μM]
(vs. cisplatin
[IC50 161.25 μM / 51.64 μM / 64.74 μM])
Volarevic et al (2013) 58
meddch IV
H, Me, Et, 
n-Pr and 
n-Bu
Glioma (C6 and U251), fi brosarcoma (L929)
and melanoma (B16) more potently
IC50 value  1.9–8.7 μM compare to  cisplatin
(IC50 10.9–67.0 μM)
Lazić et al (2010) 59
Me, Et, n-Pr 
and n-Bu
human melanoma (A375), human 
glioblastoma (U251), human prostate cancer 
(PC3), human colon cancer (HCT116), mouse 
melanoma (B16) and mouse colon cancer 
(CT26CL25) cells
more potently IC50 value of Pt complexes ca. 2.9-21.3 μM (vs. cisplatin [IC50 ca. 12.5-120 μM])
Mihajlovic et al (2012) 63
eddl
II Et, n-Pr, n-Bu, n-Pe chronic lymphocytic leukemia (CLL) more potently
IC50 value (form Et to n-Pe) 22.35 μM / 9.85 
μM / 5.39 μM / 10.37 μM
(vs. cisplatin [IC50 263.75 μM])
Vujic et al (2011) 60
IV Et, n-Pr, n-Bu, n-Pe
human breast cancer (MDA-MB-361 and 
MDA-MB-453), T-leukemia (Jurkat), chronic 
myelogenous leukemia (K562), colorectal 
cancer (SW480) and CLL lymphocytes
more potently 
only for SW480 
cells, for other 
cell types lower 
or comparable
SW480 cells: IC50 value of Pt complexes (form 
Et to n-Pe) 5.09 μM / 2.32 μM / 3.95 μM / 0.74 
μM (vs. cisplatin [IC50 31.92 μM])
Vujic et al (2012) 61
eddch IV Me, Et, n-Pr, n-Bu
human glioblastoma (U251), mouse 
melanoma (B16) more potently
U251 cells: IC50 value of Pt complexes ca. 1.9-
17.5 μM (vs. cisplatin [IC50 ca. 20.0 μM])
B16 cells: IC50 value of Pt complexes ca. 3.1-
21.3 μM (vs. cisplatin [IC50 ca. 94.3 μM])
Mihajlovic et al (2013) 64
(S,S)-1,3-
propanediamine-
N,N’-di-2-(3-
cyclohexyl)
propanoic acid
II i-Bu; n-Pe and i-Pe/J
 human neoplastic cell lines (HeLa, A549, 
MDA-MB-231, LS-174, EA.hy 926), and 
human fetal lung fi broblast cell line (MRC-5)
more potently 
(n-Pe Pt(II)
complex)
n-Pe Pt(II) complex IC50 value 5.4 μM / 11.1 
μM / 11.9 μM / 12.2 μM/ 5.9 μM (vs. cisplatin 
[IC50 6.9 μM/ 17.2 μM / 15.4 μM/ 21.9 μM/ 22.4 
μM])
Savic et al (2014) 65
(S,S)-eddba IV Et, n - Pr, n-Bu chronic lymphocytic leukemia (CLL) more potently
IC50 value of Pt complexes (form Et to n-Bu) 
5.04 μM / 6.08 μM / 25.28 μM (vs. cisplatin 
[IC50 331.61 μM])
Dimitrijevci et al (2013) 66
N/A- not applicable
290
cisplatin and complexes with edda ligands (cis-[PtCl2 
(edda)]) (49). There is a high probability that difference in 
effects stems from otherwise complex geometry. These 
two complexes will obtain dissimilar adducts with cell 
molecules (DNA nucleic bases) by direct interaction. How-
ever, if reduction process (Pt(IV) to Pt(II)) occurs before in-
teraction with nucleic bases, trans-[PtX2(eddp)] complexes 
will form tetracoordinated platinum(II) complexes where 
eddp ligand occupies all four coordination positions pre-
venting in that way reaction with DNA nucleic bases (49). 
In the contrary, reduction of cis-[PtCl2(edda)] complex, by 
formatting tetracoordinated platinum(II) complexes which 
contain biscoordinated edda ligand and leaving two chloro 
ligands which could easily be replaced and make a link 
with DNA (49). Also, some studies of platinum(II)/(IV) 
complexes ([PtCl4(Bu2eddp)], [PtBr3Cl(Bu2eddp)], [Pt-
Cl2I2(Bu2eddp)], [PtCl4(Pe2eddp)], [PtCl2(Bu2eddp)]) have 
demonstrated that these complexes had five times weaker 
cytotoxic effect on HeLa (human cervix adenocarcinoma) 
cell line compared to cisplatin, but the effect on K562 (hu-
man myelogenous leukemia) cell line was almost equal to 
the effect of cisplatin (Table 1) (50). It was concluded that 
the exchange of two chloro ions for two iodo ions in pres-
1411HP cell line. All of them induce apoptosis and their 
effect is dose-dependent. Platinum(II) complexes with bi-
dentate edda ligand type [PtCl2(R2edda)] (R = Me, Et, n-Pr; 
edda = ethylenediamine-N, N’-diacetate) were also ques-
tioned (48). In vitro cytotoxic effect was studied on various 
cell lines to generate new evidence regarding the cytotoxic 
effect of these complexes, (Table 1). The aforementioned 
trend of the impact of alkyl chain (in ester group) length on 
antitumor activity can also be applied in this case, except of 
HTC-8 and HT-29 cells. Thus, the highest cytotoxic effect 
has been achieved by [PtCl2(n-Pr2edda)] against A2780 
cells. However, the activities of all these new platinum (II) 
compounds is lower compared to the appropriate plati-
num(IV) complexes, as well as cisplatin.
Platinum complexes with eddp
and eddip-type ligands 
Grow inhibition which had been provided by influence 
of two new platinum(IV) complexes ([PtX2(eddp)] x n H20; 
X= Cl/Br; n = 1 or 1,24; eddp=ethylenediamine-N, N’- 
di-3-propionate) on A2780/A2780cisR pair of human ovari-
an cancer cell lines, showed that trans-[PtX2(eddp)] (x= Cl-, 
Br-) complexes have far less cytotoxic affinity compared to 
Figure 3. Structural formulae of platinum compounds with R2edda ligand type
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tin condensation in HeLa cells, but contrary to previous 
mentioned complexes which cause rounding of cells, this 
complex caused more irregular cell shapes which may indi-
cate that disruption of cytoskeleton and/or plasma mem-
brane may be occurred. Two new platinum(IV) complexes, 
and there in vitro activities, were demonstrated - [PtX-
2(S,S-eddp)] x nH2O (S,S-eddp = ethylenediamine-N, N’-
di-S,S-2-propanoate ion, X = chlorido or bromido, n = 4, 0) 
(55). The complexes  displayed significantly lower cytotox-
icity on severe cell lines and have a quite different mecha-
nism of action compared to cisplatin (Table 1). Also ex-
change of tetradentate eddp ligand with bidentate eddp 
ester ligand will lead to enhancement in cytotoxicity of 
platinum(IV) complexes. Stojkovic et al. (56) synthesized 
three new platinum(IV) complexes with bidentate N, 
N’-ligands, [PtCl4(R2-S,S-eddp)] (R=n-Pr, n-Bu, n-Pe). It 
has been shown that all three new complexes have a dose 
and time-dependent grow-inhibition effect. [PtCl4(n-Pr2-
S,S-eddp)] and [PtCl4(n-Pe2-S,S-eddp)] had much higher 
antiproliferative activity in comparison with cisplatin. 
Also, MDA-MD-231 cell line showed to be less sensitive to 
the treatment with all these complexes, including cisplatin. 
The greatest cytotoxic effect on HTC-116 cell line was 
demonstrated by [PtCl4(n-Pe2-S,S-eddp)] and on the oth-
er side greatest effect on a MDA-MB-231 was made by 
[PtCl4(n-Pr2-S,S-eddp)]. All this compounds induced a type 
of programmed cell death, but the third complex ([PtCl4 
(n-Pe2-S,S-eddp)]) had highest proapoptotic effect. Cyto-
toxic effect of two platinum(IV) complexes ([PtCl4(R2ed-
dp)]) (R= iPr (isopropyl) or iBu (isobutyl)) and three plati-
num(II)/(IV) complexes ([PtCl2/4(R2eddip)]) (R= iPr (iso-
propyl), iBu (isobutyl) or c-Pe (cyclopentyl)) was examined 
on various cancer cell lines (Table 1) (57). Increasing the 
number of hydrophobic alkyl side chains appears to result 
in enhancement of cytotoxicity, in fact complexes with iso-
propyl group had less activity then those with isobutyl or 
cyclopentyl group. Platinum(II) (eddip) complexes with 
isobutyl group have proven to be more effective on 
HCT116 and SW620 cells then cisplatin, as was the effect 
of these types of complexes with cyclopentyl group on CT-
26CL25, HCT116, SW6220 and B16 cells (Table 1). No 
signs of toxicity on normal primary cells (fibroblasts and 
keratinocytes) of complexes was found. All of these new 
platinum compounds induce caspase-dependent apopto-
sis. Moreover, ROS (reactive oxygen species) and RNS 
(reactive nitrogen species) are not being singled out as the 
main mediators of toxicity. On the same human colon can-
cer cell lines Volarevic et al. (58) examined the antiprolifer-
ative effect of four new platinum(II) complexes with 
O,O’-dialkyl esters of (S,S)-ethylenediamine- N, N’-di-2-(4-
methyl) pentanoic acid (alkyl, ethyl, propyl, n-butyl, n-pen-
tyl). In comparison to cisplatin all these new complexes 
have shown a higher cytotoxic activity. Conclusion of this 
study indicated that the shorter the ester chain in complex 
is, the complex will show less cytotoxic activity. Thus, the 
greatest impact was expected from platinum(II) complex 
with O,O’-dipentyl esters. Still, highest impact on human 
ent complexes will only decrease the antitumor activity of 
the complexes. It has been shown that these complexes in-
duce apoptosis, but in some cells secondary necrosis was 
detected (50). Several complexes of platinum(II)/(IV) were 
investigated in the light of in vitro antitumor activity 
against some mouse and human cell lines (Table 1) (51). Of 
all of the complexes whose efficiency was studied (trans- 
[PtCl2(pdda)], trans- [PtBr2(pdda)], trans- [PtCl2(eddp)], 
trans- [PtBr2(eddp)], [PtCl2(H2eddp)], [PtCl4(Pe2eddp)], 
[PtCl2(Bu2eddp)], [PtCl4(Bu2eddp)]), best results were 
gained with platinum(IV) complexes [PtCl4(R2eddp)] (R= 
Bu or Pe). These two complexes showed the cytotoxic 
activity was dose-depended and comparable with cis-
platin, but also that they archive cytotoxic effect more 
rapidly than cisplatin. Further examination of toxicity of 
[PtCl4(Pe2eddp)] and [PtCl4(Bu2eddp)] pointed out that 
these complexes cause ROI (reactive oxygen interme-
diates)-dependent, ERK (extracellular signal-regulated 
kinase)-independent induction of tumor cell necrosis 
as opposed to cisplatin - it induced ROI-independent 
apoptotic death of tumor cells (48). Cytotoxic effect of 
two more platinum(IV) complexes, [PtCl4(Et2eddp)] 
and [PtCl4(n-Pr2eddp)], has been investigated on severe 
cell lines but each one of them showed less activity in vitro 
in regard to cisplatin (Table 1) (52). Kaludjerovic et al. (52) 
also established that there is an interaction between plas-
mid pBR322 DNA and platinum(II)/(IV) complexes, in the 
presence or absence of ascorbic acid. From all of the plati-
num (eddp) complexes, [PtCl4(n-Bu2eddp)] is the only one 
which has in vivo anti-tumor activity demonstrated (53). 
Cytotoxic effect of [PtCl4(n-Bu2eddp)] is dose and time de-
pendent, and this complex shows its effect faster then cis-
platin against B16 melanoma cells. Investigation on mice 
examined platinum(IV) complex demonstrated greater ef-
ficiency then cisplatin in terms of reducing volume of a 
tumor in its appropriate doses. The greater advantage over 
the cisplatin is reflected in the absence of kidney damage; 
[PtCl4(n-Bu2eddp)] did not show any sign of nephrotoxicity 
(53). A new modification of platinum(II/IV) complexes 
with R2(S,S)eddp ligand type (O,O’-di-isopropyl or O,O’-di-
isobutyl- (S,S)-ethylenediamide-N, N’-di-2-propionate) 
were synthetized (Table 1) (54). The results showed that 
the Pt(IV)complexes were followed with better cytotoxic 
activity. Also, it has been noted that if in platinum(II) com-
plexes with this ligand type occur the interchange isopro-
pyl group for isobutyl group, cytotoxic activity will be in-
creased. On the other hand, if this exchange occurs in 
platinum(IV) complexes, the cytotoxic activity will be de-
creased, regardless of the type of cell line. However, the 
best activity has been demonstrated by platinum(IV) com-
plex with O,O’-di-isopropyl-(S,S)-ethylenediamide-N, 
N’-di-2-propionate ligand against K526 and Fem-x cell 
lines, unfortunately each one of these complexes had lower 
cytotoxic activity (2-5 times) in comparison to the corre-
sponding cisplatin. Complexes [PtCl2{(S,S)-iBu2eddip}], 
[PtCl4{(S,S)-iPr2eddip}] and [PtCl4{(S,S)-iBu2eddip}] induce 
apoptosis. Complex [PtCl2{(S,S)-iPr2eddip}] led to chroma-
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treatment with cisplatin (Table 1). These platinum(IV) 
complexes with eddch ligand type induce apoptosis, but 
in lower dose range, and it has been shown that they affect 
primary keratinocytes and fibroblasts less then cisplatin, 
which may be indicative of their selectivity. Furthermore, 
series of complex electrochemical tests were performed 
by cyclic voltammetry and differential pulse voltamme-
try (64). This study indicated that the reduction of these 
complexes is performed as two-electron process followed 
by the loss of axial chloride ligand and the length of the 
C atom chain in esters part affects the reduction poten-
tial. Correlation between redox potentials and IC50 (half 
maximal inhibitory concentration) values was not estab-
lished. Pt(II)-iododo complexes with derivatives of ethyl-
enediamine-N, N’-diacetate (edda)-type of ligands, (esters 
of (S,S)-1,3-propanediamine-N, N’-di-2-(3-cyclohexyl)pro-
panoic acid) are also a new potential anticancer substance 
(65). Cytotoxic effect of isobutyl, n-pentyl and isopentyl 
esters of these compounds were examined against various 
human cell lines (Table 1). Although summary effect of all 
these compounds was better in regard to cisplatin, in LS-
174 cells effect was 3 to 4 times higher than golden stand-
ard. However, exanimate complexes seem to have a dif-
ferent mode of mechanism which includes apoptotic and 
necrotic elements of cell death. These complexes also evince 
better affinity for DNA binding then cisplatin and enter cells 
efficiently, which may be an important advantage in respect of 
avoiding cell resistance. Better intracellular accumulation and 
DNA binding are probably the result of substitution kinetics 
of iodide ligands and proper lipophilicity of an edda ligand 
type. The cytotoxic effect against freshly isolated CLL cells 
is achieved by [PtCl4(R2-S,S-eddba)] (R= Et, Pr or Bu) (edd-
ba-ethylenediamine-N, N’-di-S,S-(2,2’-dibenzyl)acetic acid) 
complex, as reported by Dimitrijevic et al. (66). The cytotoxic 
influence of [PtCl4(Et2-S,S-eddba)] and [PtCl4(Pr2-S,S-eddba)] 
was better than complex with n-butyl group in ester chain, 
but still, all of them have considerably higher antiproliferative 
ability against CLL cells then cisplatin (Table 1). 
CONCLUSION
The design of platinum based drugs is not a new field of 
interest. This article summarizes recent research progress 
in research on edda-type-platinum complexes - new type of 
platinum based drugs. Some of these compounds achieves 
better effect compared with the gold standard (cisplatin). 
Of particular interest are the noticeable effect of some new 
platinum compound with edda ligand type on cell lines 
which are known to have a high level of cisplatin-resist-
ance. There are indications that further investigations of 
these compounds may be very useful in overcoming the 
problems with global cancer statistic. Further preclinical 
and clinical researches might give some useful information 
which can help in overcoming the main problems related 
to platinum based drugs (including tumor resistance and 
less serious side effect).
colon cancer cells (especially on HTC116) has been made 
by platinum(II) complex with O,O’-dibutyl esters. It is 
thought that the reason for this is the superior intercellular 
accumulation (59).
Platinum complexes with meddch-, eddl-, eddch
and eddba- type ligands 
Recently, platinum(II) and platinum(IV) complexes 
with (S,S)-R2eddl ligand type have been synthetized (60,61). 
Highest activity had come from complexes with n- butyl 
group in ester chain [PtCln((S,S)-R2eddl)] (R= Et, Pr, n-Bu 
or n-Pe; n=2 or 4; O,O’-diethyl-(S,S)-ethylenediamine-N, 
N’-di-2-(4-methyl)-pentanoate)platinum), although cy-
totoxic effect increases with the increase of ester chain 
length, as previously mentioned. This type of platinum(II) 
complexes were found to display much higher antitumor 
activities on CLL cells in comparison to cisplatin (60), 
especially [PtCl2((S,S)-n-Bu2eddl)], which is the bearer of 
the highest antitumor activity of them all. Platinum(IV) 
compounds with (S,S)-R2eddl ligand type were appraised 
for their cytotoxic effect (Table 1) (61). Very potent com-
plex was also the one with n-butyl group in ester chain 
[PtCl4((S,S)-n-Bu2eddl)]. It is interesting that CLL cells 
is the only cell line more sensitive on platinum(II) com-
plex. Lazic et al. (59), synthesized a new platinum(IV) 
compound with tetradentate coordinated (S,S)-ethylene-
diamine-N,N′-di-2-(3-cyclohexyl) propanoate (cyclohex-
yl edda/eddch). The cytotoxic effect of these complexes 
[PtCl4((S,S)-R2eddch)] (R= Me, Et, n-Pr, n-Bu) were tested 
against various cell lines (Table 1). All compounds were 
clearly more cytotoxic than cisplatin, especially against 
cisplatin-resistant B16 cells. They also suggested that the 
length of alkyl chain has different effect than is the case 
with other platinum complexes. The longer the alkyl chain 
is, the poorer is the antitumor activity. They also cleared 
the difference which existed between mechanisms of ac-
tion of these complexes and golden standard. Cisplatin 
brings about caspase-dependent apoptosis realized by an 
autophagy response. On the other hand, new octahedral 
platinum(IV) complexes induce necrosis like cell death. 
Soon after, there was a report of octahedral Pt(IV) com-
plex with di-n-propyl-(S,S)-ethylenediamine-N, N’-di-
2-(3-cyclohexyl)propanoato ligand and its effect on im-
mune cells (SPC and LNC) (62). It has been shown that 
this platinum(IV) complex, in concentrations which have 
been proven effective on tumor cells, does not notably 
affect viability of immune cells. Also, this complex disen-
ables synthesis of IFN-γ, IL-17 and NO in immune cells. 
The new prospective platinum(IV) drugs were synthe-
sized with the novel N,N′-methylene modified cyclohexyl 
ethylenediamine-N,N′-diacetate (edda)-type ligands, [Pt-
Cl4((S,S)-R2meddch)] (R= Me, Et, n-Pr, n-Bu) (63). All of 
these compounds, with the exemption of [PtCl4((S,S)-Me-
2meddch)], demonstrated higher citotoxic activity then 
cisplatin on every cell line, especially on HCT116 and 
CT26CL25 cell lines resistant or poorly responsive to 
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